Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 55
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PF324CA6511EN
Leaflet:

Download PDF Leaflet

Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Polycystic Ovarian Syndrome - Pipeline Review, H2 2016’, provides an overview of the Polycystic Ovarian Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome
  • The report reviews pipeline therapeutics for Polycystic Ovarian Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Polycystic Ovarian Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Polycystic Ovarian Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Polycystic Ovarian Syndrome Overview
Therapeutics Development
Pipeline Products for Polycystic Ovarian Syndrome - Overview
Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis
Polycystic Ovarian Syndrome - Therapeutics under Development by Companies
Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes
Polycystic Ovarian Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Polycystic Ovarian Syndrome - Products under Development by Companies
Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Crinetics Pharmaceuticals, Inc.
EffRx Pharmaceuticals S.A.
Euroscreen S.A.
Merck KGaA
Millendo Therapeutics, Inc.
Vicore Pharma AB
Polycystic Ovarian Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
C-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
choriogonadotropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDSCR-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metformin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MLE-4901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycystic Ovarian Syndrome - Dormant Projects
Polycystic Ovarian Syndrome - Discontinued Products
Polycystic Ovarian Syndrome - Product Development Milestones
Featured News & Press Releases
Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome
Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients
Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations
Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H2 2016
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H2 2016
Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H2 2016
Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H2 2016
Polycystic Ovarian Syndrome - Pipeline by Millendo Therapeutics, Inc., H2 2016
Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Polycystic Ovarian Syndrome - Dormant Projects, H2 2016
Polycystic Ovarian Syndrome - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Addex Therapeutics Ltd
Crinetics Pharmaceuticals, Inc.
EffRx Pharmaceuticals S.A.
Euroscreen S.A.
Merck KGaA
Millendo Therapeutics, Inc.
Vicore Pharma AB
Skip to top


Ask Your Question

Polycystic Ovarian Syndrome - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: